BD’s foot science footprint is getting a lot bigger – 220,000 square feet to be precise.
The medical technology giant has signed a lease for a new research and development facility in San Diego, where its BD Biosciences division has long been present. The new real estate acquisition will serve as an expanded reagent innovation center for the segment developing tools and reagents for flow cytometry, single cell multiomics, immuno-oncology and, more recently, COVID-19 research.
The facility on the Torrey View campus of life sciences-focused real estate development company Breakthrough Properties is expected to be completed in the second half of 2023.
âOur new facility in San Diego will help improve our research, development and operations capabilities and position BD for exciting growth. BD Biosciences is a cornerstone of BD’s mission to advance the world of health by providing researchers with innovative tools that advance deeper understanding of the immune system and unleash its unique power to fight disease, âsaid Puneet Sarin, Global President of BD Biosciences in a statement.
RELATED: BD Signs BARDA Contract To Develop COVID Tests For The Long Future Of The Pandemic
BD Biosciences’ home base in Torrey View will be housed in the largest of the three R&D buildings planned for the 10 acre campus and will occupy almost half of the total available space on the property. BD is so far the first powerhouse in the life sciences sector to have signed a significant pre-approval for the property.
The additional 220,000 square feet will give BD plenty of space to build on its existing presence in San Diego, where more than 4,000 of its employees already work, said Steve Conly, vice president and general manager of BD Biosciences Research Solutions. The property is located in the Del Mar Heights neighborhood of San Diego, near working-class housing for the many biopharmaceutical companies that have settled in the area.
“The site was chosen after careful consideration of a number of alternatives and is testament to our commitment to recruiting and developing members of the San Diego community,” Conly said in a statement.
In addition to the three R&D facilities, Torrey View will offer its tenants a wide variety of amenities. This includes indoor and outdoor meeting rooms, dining areas, a fitness center, pickleball courts, and on-site parking. The campus is also environmentally friendly, with LEED efficiency certifications for the buildings and landscaping with drought tolerant native plants and plenty of open green spaces and gardens.
In addition, as with other Breakthrough Properties locations, BD and its co-tenants can collaborate in the Torrey View Life Sciences Ecosystem and access the Breakthrough Scientific Advisory Board.
RELATED: BD Suspends FDA Approval for Automated Molecular Diagnostics Platform with Initial Test for HPV
The San Diego expansion marks BD’s second property acquisition this month alone. Just last week the company broke ground for a new plant in Zaragoza, Spain, where it will manufacture prefillable syringes and other drug delivery devices. The 86,000 square meter site is due to be completed by the end of 2023 and will cost BD 165 million euros.